Epi-drugs as triple-negative breast cancer treatment - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Epigenomics Année : 2020

Epi-drugs as triple-negative breast cancer treatment

Résumé

Triple-negative breast cancer (TNBC) types with poor prognosis are due to the absence of estrogen receptors, progesterone receptors and HEGFR-2. The lack of suitable therapy for TNBC has led the research community to turn toward epigenetic regulation and its protagonists that can modulate certain oncogenes and tumor suppressors. This has opened an important new field of therapy using epi-drugs, in preclinical and clinical trials. The epi-drugs are natural or synthetic molecules capable of inhibiting or modulating the activity of epigenetic proteins such as DNA methyltransferases, modulating the expression of interferon microRNAs, as well as histone methyltransferases, demethylases, acetyltransferases and deacetylases. This review investigated the epi-drugs used in the treatment of TNBC.
Fichier non déposé

Dates et versions

hal-02882168 , version 1 (26-06-2020)

Identifiants

Citer

Mouhamed Idrissou, Anna Sanchez, Frédérique Penault-Llorca, Yves-Jean Bignon, Dominique Bernard-Gallon. Epi-drugs as triple-negative breast cancer treatment. Epigenomics, 2020, ⟨10.2217/epi-2019-0312⟩. ⟨hal-02882168⟩
35 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More